← brief for 2026-09-01 · Transplant & xeno

Effects of dapagliflozin on proteinuria, glycemic control, and treatment burden in diabetic kidney transplant recipients: a matched cohort study.

Key takeaways

Dapagliflozin is an SGLT2 inhibitor, a diabetes drug that also protects kidneys in people with chronic kidney disease. Doctors compared kidney transplant recipients with diabetes who took it against closely matched recipients who did not. They tracked protein in the urine, blood sugar, how well the transplanted kidney worked, and how many other medicines people had to take. Because people were not randomly assigned, this shows a link, not proof of cause, and evidence in transplant recipients is still thin.

Who did this work

Ural Z · Derici U

Source

Article · PubMed, the drug frontier · 2026 Sep 1
https://pubmed.ncbi.nlm.nih.gov/42675203/